The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

The Center for Biological Diversity sued the Trump administration today for failing to release the names of fossil fuel companies and other polluters seeking exemptions from life-saving Clean Air Act ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

On May 6, 2025, the Global Initiative For Asthma (GINA) published the 2025 update to their Global Strategy for Asthma Management and Prevention guidance report. Chair of the GINA Dissemination Working ...

This updated asthma guideline establishes a consistent approach to improving asthma diagnosis and control in adults and ...

Medical experts are dismayed over a federal report's claim that kids are overprescribed asthma medications, saying it ...

Dupilumab use in asthma is linked to higher lymphoma risk, especially T and NK cell types, but also shows reduced all-cause ...